1. Home
  2. ECBK vs VERU Comparison

ECBK vs VERU Comparison

Compare ECBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

N/A

Current Price

$20.32

Market Cap

182.5M

Sector

Finance

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.45

Market Cap

44.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECBK
VERU
Founded
1919
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.5M
44.0M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
ECBK
VERU
Price
$20.32
$2.45
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
5.5K
199.1K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
95.83
N/A
EPS
0.77
N/A
Revenue
$598,000.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.78
N/A
Revenue Growth
3.64
N/A
52 Week Low
$14.83
$2.05
52 Week High
$21.51
$7.33

Technical Indicators

Market Signals
Indicator
ECBK
VERU
Relative Strength Index (RSI) 45.72 43.35
Support Level $20.03 $2.12
Resistance Level $20.79 $2.67
Average True Range (ATR) 0.45 0.14
MACD -0.07 -0.03
Stochastic Oscillator 8.46 5.14

Price Performance

Historical Comparison
ECBK
VERU

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: